中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 国家级研究中心
  5. 原创新药研究全国重点实验室
Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma

文献类型：期刊论文

作者Shi, Wenhao1; Tang, Haotian1,2,3; Tong, Linjiang2,3; Song, Peiran1; Huang, Yuqing1; Wan, Zhipeng1; Huang, Gege1; Liu, Qiupei1,6; Zhan, Zhengsheng4; Zhou, Yu1
刊名CANCER CELL INTERNATIONAL
出版日期2025-07-25
卷号25期号:1页码:12
关键词SYHA1813 Melanoma VEGFR2 CSF1R Metastasis Vemurafenib
DOI10.1186/s12935-025-03902-y
英文摘要BackgroundMelanoma is notorious for its aggressive growth, metastatic spread, and heterogeneous response to therapy across BRAF (B-Raf proto-oncogene, serine/threonine kinase) genotypes. While BRAF inhibitors improve outcomes in V600E-mutant tumors, their benefit is limited in wild-type melanomas and by transient responses in mutant disease. Vascular endothelial growth factor receptor 2 (VEGFR2) driven angiogenesis and colony-stimulating factor-1 receptor (CSF1R) mediated immunosuppression each sculpt a permissive tumor microenvironment. We hypothesized that simultaneous blockade of both axes with SYHA1813, which currently undergoing Phase II clinical trials in China for solid tumor treatment, would yield a broadly applicable, microenvironment-targeted strategy for melanoma treatment.MethodsSubcutaneous xenograft models of BRAF wild-type (MeWo) and BRAF V600E-mutant (A375) melanoma were established (NOD-SCID mice), alongside an intracardiac metastasis model (Nude mice) using GFP-Luc-labeled A375 cells. SYHA1813 (2.5 mg/kg or 5 mg/kg), alone or combined with vemurafenib (20 mg/kg), was administered to assess tumor growth, metastatic burden, and microenvironmental modulation. Tumor growth inhibition rates and synergistic effects were quantified. The markers of angiogenesis, macrophage polarization and cell proliferation were analyzed via immunohistochemistry.ResultsSYHA1813 monotherapy exhibited significant antitumor efficacy in BRAF wild-type MeWo and BRAF V600E-mutant A375 melanoma xenograft models at 5 mg/kg, achieving 72.5% and 79.8% tumor growth inhibition, respectively, surpassing vemurafenib in BRAF wild-type tumors. Treatment regimens were well tolerated, with no significant body weight changes observed. Mechanistically, SYHA1813 suppressed angiogenesis, attenuated M2 macrophage infiltration, and inhibited tumor cell proliferation as marked by reduced CD31, CD105, F4/80, CD206 and Ki67 expression. Moreover, we evaluated the combination of SYHA1813 with vemurafenib in BRAF V600E-mutant models and found that 2.5 mg/kg SYHA1813 treatment synergized with vemurafenib, enhancing tumor suppression to 72.9% inhibition compared to each monotherapy (38.9% and 34.7%, respectively). Furthermore, we established a systemic intracardiac metastasis mouse model to assess the impact of SYHA1813 on melanoma metastasis. The results showed that SYHA1813 reduced systemic metastasis by 76.6%, significantly curtailing brain and bone metastases.ConclusionsDual targeting of VEGFR2 and CSF1R with SYHA1813 confers a novel microenvironmentcentric strategy for treating both BRAF wildtype and mutant melanoma. By concurrently disrupting angiogenesis and macrophagemediated immunosuppression, SYHA1813 demonstrates strong therapeutic and antimetastatic activity to melanoma, warranting further clinical development as monotherapy or in combination with BRAF V600E inhibitors.
WOS关键词TUMOR ; MICROENVIRONMENT ; INHIBITION ; BIOLOGY
资助项目National Key Research and Development Program of China
WOS研究方向Oncology
语种英语
WOS记录号WOS:001537293700002
出版者BMC
源URL[http://119.78.100.183/handle/2S10ELR8/321114]  
专题国家级研究中心_原创新药研究全国重点实验室
通讯作者Li, Xiaorui; Xie, Hua
作者单位1.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China
3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
4.Chinese Acad Sci, Shanghai Inst Mat Med, Small Mol Drug Res Ctr, Shanghai 201203, Peoples R China
5.Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai 200032, Peoples R China
6.Univ Nottingham Ningbo China, Dept Chem & Environm Engn, Sci & Engn Bldg, Ningbo 315100, Peoples R China
推荐引用方式
GB/T 7714		 Shi, Wenhao,Tang, Haotian,Tong, Linjiang,et al. Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma[J]. CANCER CELL INTERNATIONAL,2025,25(1):12.
APA Shi, Wenhao.,Tang, Haotian.,Tong, Linjiang.,Song, Peiran.,Huang, Yuqing.,...&Xie, Hua.(2025).Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma.CANCER CELL INTERNATIONAL,25(1),12.
MLA Shi, Wenhao,et al."Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma".CANCER CELL INTERNATIONAL 25.1(2025):12.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。